Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XIAP | P98170 | 1/20 | 0.43 |
| ▸ | GPER1 | Q99527 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 4/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL330671 | 0.90 | PLTP (0.41) | XIAPMEN1KMT2ANPC1RAB9A | |
| SCHEMBL330487 | 0.88 | MEN1 (0.46) | XIAPMEN1KMT2ANPC1RAB9A | |
| SCHEMBL330992 | 0.84 | XIAP (0.56) | XIAPMEN1KMT2ANPC1RAB9A | |
| SCHEMBL3278381 | 0.83 | XIAP (0.47) | XIAPMEN1KMT2ANPC1RAB9A | |
| SCHEMBL332059 | 0.81 | TMPRSS4 (0.49) | XIAPMEN1KMT2ANPC1RAB9A | |
| SCHEMBL330283 | 0.81 | GPER1 (0.44) | GPER1MEN1KMT2ASORT1 | |
| SCHEMBL330259 | 0.79 | KMT2A (0.60) | XIAPMEN1KMT2ANPC1RAB9A | |
| SCHEMBL330674 | 0.77 | RAB9A (0.64) | MEN1KMT2ANPC1RAB9ARXFP1 | |
| SCHEMBL3278037 | 0.77 | ADORA3 (0.52) | XIAPMEN1KMT2ANPC1RAB9A | |
| SCHEMBL329799 | 0.77 | MEN1 (0.64) | MEN1KMT2ARXFP1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8263657-B2 | Blocking neurokinins; using a benzene compound containing hydroxy or acetoxy group; antiinflammatory agents | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2012-09-11 | — | — | US | disclosed |
| CN-101849953-B | Inflammatory cytokine release inhibitor | INST MED MOLECULAR DESIGN INC | 2012-04-25 | — | — | CN | disclosed |
| US-8097759-B2 | Inflammatory cytokine release inhibitor | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-20100274051-A1 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) | 2010-10-28 | — | — | US | disclosed |
| CN-101849953-A | Inflammatory cytokine release inhibitor | INST MED MOLECULAR DESIGN INC | 2010-10-06 | — | — | CN | disclosed |
| US-20080318956-A1 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) | 2008-12-25 | — | — | US | disclosed |
| CN-100370975-C | Inflammatory cytokine production dissociation inhibitor | INST OF MEDICINE MOLECULAR DES (JP) | 2008-02-27 | — | — | CN | disclosed |
| CN-101125138-A | Inhibitors against the production and release of inflammatory cytokines | INST MED MOLECULAR DESIGN INC (JP) | 2008-02-20 | — | — | CN | disclosed |
| EP-1847263-A2 | Inhibitors against the production and release of inflammatory cytokines | Institute of Medicinal Molecular Design, Inc. (JP) | 2007-10-24 | — | — | EP | disclosed |
| EP-1844766-A2 | Inhibitors against the production and release of inflammatory cytokines | Institute of Medicinal Molecular Design, Inc. (JP) | 2007-10-17 | — | — | EP | disclosed |
| US-20040259877-A1 | Inhibitors against the production and release of inflammatory cytokines | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2004-12-23 | — | — | US | disclosed |
| CN-1489458-A | Inflammatory cytokine production dissociation inhibitor | ��ʽ����ҽҩ��������о��� | 2004-04-14 | — | — | CN | disclosed |
| EP-1352650-A1 | INHIBITORS AGAINST THE PRODUCTION AND RELEASE OF INFLAMMATORY CYTOKINES | Institute of Medicinal Molecular Design, Inc. (JP) | 2003-10-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100274051-A1 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | IL1B, NFKBIA, IL1A | XIAP 993/4885GPER1 1654/4885MEN1 4495/4885 |
| US-20080318956-A1 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | IL1B, NFKBIA, IL1A | XIAP 888/4885GPER1 1620/4885MEN1 4504/4885 |
| US-20040259877-A1 | Inhibitors against the production and release of inflammatory cytokines | NFKBIA, IL1B, IKBKB | XIAP 420/4885GPER1 1725/4885MEN1 4661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.